Anterior gradient-2 (AGR2) promotes tumor growth, cell migration and cellular transformation and its enhanced expression is almost completely restricted to malignant tissues, thus making AGR2 an interesting target for the development of immunotherapeutic strategies. We investigated whether the AGR2 molecule comprises human leukocyte antigen (HLA)-A*0201-binding epitopes recognized by human cytotoxic T lymphocytes (CTLs), which could be targeted in dendritic cell (DC)-based cancer immunotherapy against colorectal cancer (CRC). We reviewed the sequence of AGR2 for peptides that could potentially bind to HLA-A*0201 with the aid of a computer-based program. Five candidate peptides with different binding scores were synthesized and tested. These peptides were then assessed for their immunogenicity to elicit specific immune responses mediated by CTLs in vitro by means of enzyme-linked immunospot assays and CTL assays. AGR2 was highly expressed in several CRC cell lines, including DK01, DLD1, KM12C, HCT-8 and HT-29. DCs pulsed with AGR2-P2 (aa 11-19; LLVALSYTL) or AGR2-P4 (aa 127-135; RIMFVDPSL) generated potent CTLs that could lyse T2 cells pulsed with AGR2-P2 or AGR2-P4 and HLA-A0201 1 AGR2-positive CRC cell lines in a strong dose-dependent and HLA-A*0201-restricted manner. In conclusion, these novel epitopes derived from AGR2 protein may be attractive candidates for DC-based immunotherapy for CRC.
INTRODUCTION
Anterior gradient-2 (AGR2) is a secreted protein that was initially described in Xenopus laevis, from which it was identified in a screen for differentially expressed genes in neural development. 1 In humans, AGR2 was first identified in studies focused on differentially expressed genes in estrogen receptor-positive breast cancers.
2 Subsequent studies showed elevated AGR2 expression in adenocarcinomas of the breast, 2 esophagus, 3 pancreas 4 and prostate. 5 Recently, it has been reported that AGR2 promotes tumor growth, cell migration and cellular transformation and is one of the specific mRNA markers for circulating tumor cells in cancer patients with gastrointestinal cancer. 6, 7 The facts that AGR2 overexpression may provide a survival benefit for tumor cells and that its enhanced expression is almost completely restricted to malignant tissues make AGR2 an interesting target for the development of immunotherapeutic strategies.
Although surgical resection is the primary therapeutic modality in colorectal cancer (CRC), patients with advanced disease showed poor survival rates and an effective approach for patients with metastasis and relapsing disease has not yet been found. Active cancer immunotherapy is extremely appealing in CRC and the immune approaches to the therapy of CRC have substantially evolved over the past years. 8 Cancer immunotherapy based on dendritic cell (DC) vaccination has exciting possibilities for the treatment of cancer. 9 A central tenet of cancer immunotherapy is the generation of an antigen-specific cytotoxic T-lymphocyte (CTL) response. 10 Tumorassociated antigens and DCs play pivotal roles in this process. DCs are well known to be the most potent professional antigen-presenting cells (APCs) and have the most powerful antigen-presenting capacity. 11 Tumor-associated antigens should be expressed in a significant proportion of tumor cells and are obligatory for the survival of tumor cells. DCs pulsed with various tumor-associated antigens have been shown to be effective in producing specific antitumor effects both in vitro and in vivo. 12 Several types of tumor antigens have been applied in CRC including tumor RNA, 13 lysates, 14 apoptotic bodies, 15 heat shock protein, 16 carcinoembryonic antigen peptide, 17, 18 carcinoembryonic antigen mRNA 13 and allogeneic tumor cells. 19 However, the identification of novel tumor antigens is urgently needed to improve the efficacy of DC-based cancer immunotherapy against CRC. Along this line, in the present study, we evaluated whether AGR2 can be used for DC-based immunotherapy for CRC.
Human leukocyte antigen (HLA)-A*0201 is at high frequencies in Northern Asia and North America and is also the most popular type (approximately 32%) in Korea. We therefore investigated whether the AGR2 molecule comprises HLA-A*0201-binding epitopes recognized by human CTLs, which could be applied to DC-based cancer immunotherapy against CRC. To achieve this, a panel of AGR2-derived antigenic peptide was predicted by using a computer-based program. Five candidate peptides with different binding scores were synthesized and tested for their binding affinities to HLA-A*0201 molecules. These peptides were then assessed for their immunogenicity to elicit specific immune responses mediated by CTLs in vitro by means of enzyme-linked immunospot (ELISPOT) assays and CTL assays.
MATERIALS AND METHODS

Target cell lines
The human CRC cell lines used as target cells were as follows: DK01, DLD-1, HCT-8, KM12C, SW620 (all HLA-A*0201
1 and -A*2402 1 ), HCT-116 (HLA-A*0101
1 and -A*0201 1 ) and HT-29 (HLA-A*24 1 ). All cell lines were purchased from the American Type Culture Collection (Rockville, MD, USA) and were maintained in RPMI-1640 supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (PS) (all from Gibco-BRL, Grand Island, NY, USA). K562 cells obtained from the Korea Cell Line Bank (Seoul, Korea) were used as natural killer cell-sensitive targets.
Generation of DCs
Peripheral blood was collected from HLA-A*0201 1 healthy donors after obtaining informed consent and as approved by the institutional ethical committee of the Chonnam National University Hwasun Hospital. The monocytes were isolated by two-step density gradient centrifugation followed by plastic adherence as previously reported. 20 To generate immature DCs, the adherent monocytes (purity .95%) were cultured in Iscove's modified Dulbecco's medium supplemented with 10% heatinactivated FBS and 1% PS for 6 days in 24-well plates (BD BiosciencesLabware, San Jose, CA, USA) at 5310 5 cells/well in the presence of 50 ng/ ml recombinant human granulocyte macrophage colony-stimulating factor (LG Biochemical, Daejeon, Korea) and 20 ng/ml interleukin-4 (recombinant human interleukin (rhIL)-4; PEPROTECH, Rocky Hill, NJ, USA). For the generation of AGR2-specific CTL lines, the immature DCs were cultured by using aDC1-polarizing cocktails composed of IL1b (25 ng/ml), TNF-a (50 ng/ml; PEPROTECH), interferon (recombinant IFN-a-2a)-a (3000 units/ml; Intron-A-IFN-a-2b; LG Life Science, Chonbuk, Korea), IFN-c (1000 units/ml; Strathmann Biotech, Hamburg, Germany) and poly-I:C (20 mg/ml; Sigma-Aldrich, St Louis, MO, USA).
Peptide-T2 cell-binding assay All peptides were synthesized in the PEPTRON (Daejeon, Korea). The purity of synthetic peptides was confirmed, with the use of reversedphase high-performance liquid chromatography and mass spectrometry, to be more than 98%. Synthetic peptides were dissolved in dimethyl sulfoxide or distilled water, according to the manufacturer's recommendations and were stored at 220 uC until use. Peptides binding to HLA-A*0201 molecules were measured by using the T2 cell line according to a protocol described previously. 21 Briefly, T2 cells were incubated overnight with 3 mg/ml b2-microglobulin (Sigma-Aldrich) and different concentrations of peptides, followed by washing and incubation with fluorescein isothiocyanate (FITC)-labeled anti-HLA-A*0201 monoclonal antibody (mAb) BB7.2 (BD Pharmingen, San Diego, CA, USA). After washing, cells were analyzed for levels of HLA-A*0201 expression by using a FACSAria cell sorter (Becton Dickinson, San Jose, CA, USA) and WinMDI version 2.9 (Bio-Soft Net). HLA-A*0201 expression was quantified according to the following formula: [(mean fluorescence with peptide-mean fluorescence without peptide)/mean fluorescence without peptide]3100.
AGR2 expression in CRC cell lines AGR2 surface expression of CRC cell lines was determined by serial incubation with primary rabbit anti-AGR2 mAb (ab76473; Abcam, Cambridge, UK) and secondary AffiniPure goat anti-rabbit IgG(H1L) conjugated with FITC (Jackson ImmunoResearch Laboratories, West Grove, PA, USA). According to the manufacturer's recommendation, rabbit F(ab9)2 IgG (ab37416; Abcam) was used as an isotype control. For western blot analysis, proteins in the cell extracts were separated by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and were then transferred to a nitrocellulose membrane. The nitrocellulose membrane was incubated with 5% nonfat milk in PBS and then with rabbit antihuman AGR2 polyclonal antibody (ab43043; Abcam) for 2 h at room temperature. After washing, the membrane was incubated with a horseradish peroxidase-conjugated goat anti-rabbit IgG antibody (ab6721; Abcam) for 1 h at room temperature. Immunoreactive bands were detected by using the WEST-one Western Blot Detection System (iNtRON BIOTECHNOLOGY, Daejeon, Korea) and were analyzed with the LAS-3000 imaging system (Fujifilm Corporation, Tokyo, Japan).
Immunophenotyping of DCs
Phycoerythrin-or FITC-conjugated mAbs were added to cell pellets, incubated for 30 min on ice, and washed three times before analysis. Mature DCs were stained with phycoerythrin-conjugated mAbs against CD80 and CD86. Also, DCs were stained with FITC-conjugated mAbs against CD83 and CCR7. DC phenotypes were assayed by using a FACSAria cell sorter (Becton Dickinson) and the data were analyzed with FACSDiva (Becton Dickinson) and Win MDI version 2.9 (Bio-Soft Net).
Allogeneic mixed lymphocyte reaction
Allogeneic CD3
1 T cells (purity .90%) were isolated from peripheral blood mononuclear cells from healthy donors by positive selection by magnetic activated cell separation (Miltenyi Biotec, Auburn, CA, USA). The T cells were labeled with 5(6)-carboxyfluorescein diacetate succinimidyl ester (CFSE; 5 mM; Invitrogen) for 10 min at 37 uC. After washing, the T cells (5310 4 /100 ml/well) were seeded into 96-well Ubottomed tissue culture plates in RPMI-1640 supplemented with 10% FBS and 1% PS. Various numbers of allogeneic mature DCs pulsed with or without AGR2 peptides were added to the plates and cultured for 5 days at 37 uC in 5% CO 2 . Flow cytometric analysis was used to detect dilution of CFSE. 22 Generation of AGR2-specific CTLs using HLA-A0201-restricted synthetic peptides HLA-A*0201-binding peptides derived from AGR2 (P1: LLLVALSYT; P2: LLVALSYTL; P3: KLAEQFVLL; P4: RIMFVDPSL; P5: LLLDNMKKA) and HIV-1 gp160 (KLTPLCVTL, used as an irrelevant control) were synthesized. AGR2-specific CTLs were generated in vitro by stimulation of CD8
1 lymphocytes (1310 6 ) from HLA-A2-positive healthy donors with AGR2 peptide-pulsed DCs (1310 5 -2310 5 
cells). Briefly, CD8
1 T cells (purity .90%) were positively isolated by magnetic activated cell separation (Miltenyi Biotec) from the lymphocyte fraction after Percoll isolation. The mature DCs (1310 5 -2310 5 cells)
AGR2-specific CTL in colorectal cancer HJ Lee et al 176 were pulsed with AGR2 peptides at a final concentration of 20 mg/ml at 37 uC for 2 h. Autologous T cells were cocultured with AGR2 peptidepulsed DCs in 2 ml medium (RPMI-1640/AIM-V 51:1) containing 10% FBS and 1% PS supplemented with 5 ng/ml rhIL-2, 10 ng/ml rhIL-7 and 5 ng/ml rhIL-15 (all from PEPROTECH). The medium was replenished with cytokines every 3 days. On day 10, the CTL lines were restimulated with AGR2 peptide-pulsed autologous mature DCs or monocytes. On day 17, the number of AGR2-specific T cells was analyzed by IFN-c ELISPOT kit (BD Bioscience) 23, 24 and the cytolytic activity of CTLs was examined by using a standard 51 Cr-release assay. 25 ELISPOT assay T2 cells pulsed with AGR2 peptide, HLA-A*0201 1 AGR2-positive CRC cell lines (HCT-8 and DLD1) and HLA-A*0201 1 AGR2-negative CRC cell line (HCT116) were used as target cells with or without anti-major histocompatibility complex (MHC) class I mAb (30 mg/ml) for the antigen-specific, IFN-c ELISPOT assay. The number of IFN-c spots was enumerated by an automatic CTL immunospot analyzer (Cellular Technology Ltd, Shaker Heights, OH, USA). All samples were run in triplicate, and data were expressed as the mean number of spots6standard deviation per 10 5 CD8 1 T cells. 
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Cytotoxicity assay
The standard 4-h 51 Cr-release assay was performed to measure the cytolytic activity of the T cells against target cells as described previously. 25 T2 pulsed with AGR2 peptide or HIV peptide, K562, HLA-A*0201 1 AGR2-positive CRC cell lines (HCT-8 and DLD1) and HLA-A*0201 1 AGR2-negative CRC cell line (HCT116) were used as target cells. The target cells were incubated with 100 mCi 51 Cr-sodium chromate for 1 h, washed extensively, seeded (1310 4 cells/well) into 96-well U-bottomed plates in T-cell medium and cocultured for 4 h with various numbers of CTLs. All assays were performed in triplicates. Results are expressed as the mean percentage of 51 Cr-release calculated as follows: [(experimental release2spontaneous release)/(maximum release2spontaneous release)]3100%. Maximum release was determined after adding 100 ml 2% Triton X-100 solution to the targets and spontaneous release was always less than 20% of the maximum 51 Cr uptake. To determine whether the cytolytic activity was restricted by MHC class I molecule, 30 mg/ml mAbs against HLA-ABC (W6/32) were added to the cultures at the start of the assay.
Statistical analysis
All statistical analyses were performed with the program SPSS 13.0 for Windows (SPSS Inc., Chicago, IL, USA). The Mann-Whitney U test was performed to analyze the statistical significance of non-parametric differences between the groups. P,0.05 was considered statistically significant. 
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RESULTS
AGR2 expression in several CRC cell lines
We used western blot and flow cytometric analyses to examine the expression of AGR2 in several CRC cell lines. Seven CRC cell lines, including DK01, DLD1, KM12C, HCT-8, HCT-116 and SW620, were tested. Among them, AGR2 protein was markedly expressed in five CRC cell lines in the western blot assay: DK01, DLD1, KM12C, HCT-8 and HT-29. AGR2 expression was not detected in the HCT-116 or SW620 CRC cell line (Figure 1a) . We therefore used the HCT-116 cell line as an AGR2-negative target for further study. The surface expression of AGR2 protein in CRC cell lines was also investigated. In these studies, we used the MCF-7 breast cancer cell line as an AGR2-positive control. HCT-116 and SW620 CRC cell lines were used as negative controls. As shown in Figure 1b , AGR2 was highly expressed on the surfaces of the DK01, DLD1, HCT-8 and HT-29 cell lines, indicating that AGR2 protein could be 
Selection of AGR2 peptides
Next, we reviewed the sequence of AGR2 for peptides that could potentially bind to HLA-A*0201 with the aid of a computer-based program (http://www-bimas.cit.nih.gov/molbio/hla_bind/). After comparing the predictive binding scores according to the manufacturer's recommendation, we identified and selected five peptides that could potentially bind with HLA-A*0201 molecules: two with high binding scores and three with low binding scores (Table 1) . Presumably, peptides with high binding affinity to HLA-A*0201 molecules could be seen as selfantigens by the immune system, and thus most individuals could be immunologically tolerant to these peptides. Thus, we selected additional three peptides with low binding scores. The five selected peptides were named P1, P2, P3, P4 and P5 according to their amino-acid sequence: P1 (aa 10-18), P2 (aa [11] [12] [13] [14] [15] [16] [17] [18] [19] , P3 (aa 99-107), P4 (aa 127-135) and P5 (aa 160-168). Their subsequences are shown in Table 1 . We measured and confirmed the binding affinity of the five peptides by a peptide-T2 binding assay. Actually, most peptides except P1 showed a high affinity index to the HLA-A*0201 molecules ( Figure 2 ).
Screening of AGR2 peptide-specific CTLs AGR2 specific CTLs for P1, P2, P3, P4 and P5 were evaluated by enumerating the number of IFN-c-secreting T cells using ELISPOT assay. To generate AGR2 peptide-specific T cells from HLA-A*0201 1 donors, autologous mature DCs pulsed with peptides were used as APCs. After two rounds of in vitro stimulation, CTLs were obtained that proliferated in response to autologous DCs pulsed with AGR2 peptides P1, P2, P3, P4 and P5. After restimulation with DCs pulsed with AGR2 peptides, large numbers of IFN-c-secreting cells against AGR2 peptide-pulsed T2 cells (upper panel) and AGR2-positive HCT-8 CRC cells (lower panel) were detected in AGR2 peptide P2-and P4-specific T cells, but not in AGR2 peptide P1-specific T cells (Figure 3) . Incubation of CD8 1 T cells with unpulsed DCs or with DCs pulsed with P3 or P5 did not result in CTL induction. We therefore used the AGR2 P2 and P4 peptides in further studies to characterize the cytotoxic activity of AGR2 peptide-specific T cells against CRC cells.
Characterization of DCs pulsed with AGR2 P2 or P4 peptide
We used flow cytometric analysis to determine the phenotypes of DCs pulsed with or without AGR peptide P2 or P4. As shown in Figure 4a , after 8 days of culture, cells from the above three DC populations displayed a characteristics set of mature DC surface markers. No significant difference was found in the expression of CD80, CD83, CD86 or CCR7 among them. Thus, DCs pulsed with AGR2 peptides resulted in efficient generation of mature DCs without altering the phenotype of the mature DCs. The allogeneic T-cell stimulatory capacity of DCs pulsed with or without AGR2 peptide P2 or P4 was investigated by using CFSE labeling assays. DCs pulsed with AGR2 peptide P2 or P4 1 CRC cell lines such as HCT-8 and DLD1 were used as target cells. MHC class I restriction of the CTLs was analyzed using an MHC class I-specific mAb (clone W6/32). Nonspecific response was determined by irrelevant Ig blockade. Error bars show s.d. AGR2, anterior gradient-2; CTL, cytotoxic T lymphocyte; CRC, colorectal cancer; DC, dendritic cell; ELISPOT, enzyme-linked immunospot; IFN, interferon; MHC, major histocompatibility complex; mAb, monoclonal antibody.
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In vitro CTL responses induced by DCs pulsed with AGR2 peptide P2 or P4
The functional capability of the CTL response to DCs pulsed with or without AGR2 peptide P2 or P4 was tested by determining whether the cells could specifically recognize target cells in an ELISPOT assay ( Figure 5 ) and a standard 4-h 51 Cr-release assay ( Figure 6 ). T2 cells pulsed with or without AGR2 peptide P2 or P4 (Figures 5a and 6a) , two AGR2-positive CRC cell lines (HCT-8 and DLD1) or AGR2-negative CRC cell line (HCT116) were used as target cells. The two generated effector T-cell groups (CTLs with DCs pulsed with P2 or P4) were compared for their ability to recognize T2 cells pulsed with AGR2 peptide P2 or P4 and the AGR2-positive HCT-8 and DLD1 CRC cell lines. As shown in Figure 5 , CTLs that were generated by DCs pulsed with P2 or P4 showed a large number of IFN-c-secreting cells, respectively. Those responses were specifically inhibited by incubation with MHC class I mAb (clone W6/32) incubation and no inhibitory response with irrelevant Ig blockade was seen, thus indicating that this CTL activity was immunologically specific. In addition, the AGR2-negative CRC cell line (HCT116) did not show any specific IFN-c-secreting cells for the CTLs. Representative results of 3 experiments (the numbersof spot) are shown in supplemental Figure 1 .
Cytotoxicity of AGR2 peptide P2 or P4-specific CTLs Next, we examined the cell-mediated killing of target cells in vitro by using a standard 4-h 51 Cr-release assay at various effector/ target (E/T) ratios. The cytotoxic activity of CTLs against AGR2 P2-or P4-pulsed T2 cells, two AGR2-positive CRC cell lines (HCT-8 and DLD1) or AGR2-negative CRC cell line (HCT116) is shown in Figure 6 . Two independently generated CTLs effectively lysed AGR2 peptide P2-or P4-pulsed T2 cells at several E/T ratios. This CTL activity was immunologically specific, in that none of these cells showed strong cytotoxic activities against the irrelevant HIV-pulsed T2 cells as for AGR2 P2-specific CTLs and as for AGR2 P4-specific CTLs. No killing was observed against the K562 cell line, thus excluding the possibility that natural killer cells contributed to the cytotoxicity (P,0.05 compared to HIV and P,0.01 compared to K562). Furthermore, AGR2 P2-or P4-specific CTLs strongly lysed HLA-A*0201 1 AGR2-positive CRC cells (HCT-8 and DLD1) in a dose-dependent manner, but not HLA-A*0201 1 AGR2-negative CRC cells (HCT116) (P,0.01 at an E/T ratio of 25:1, P,0.05 at E/T ratios of 12.5:1 and 6.25:1, respectively).
DISCUSSION
Over the past few years, the analysis of spontaneous immune responses to autologous tumors in cancer patients has allowed the identification of several kinds of tumor-associated antigens that can be the targets for tumor-specific immune responses based on recognition of tumor antigen by CTLs in an MHC class I/peptide complex-restricted manner. Therefore, cancer-specific immunotherapy has become an attractive therapeutic approach to carcinomas. 26 Among the approaches, one of the most relevant for the development of tumor immunotherapy is peptide-based, cancer-specific immunotherapy using antigens that are expressed in tumor but not in normal tissues. Therefore, the identification of T-cell epitopes from these antigens becomes a critical step in the development of peptide-based immunotherapy for cancer.
Previous studies have showed elevated AGR2 expression in adenocarcinomas of the breast, esophagus, pancreas and prostate. However, whether AGR2 was aberrantly expressed in CRC remained unknown. Recently, it was reported that AGR2 promotes tumor growth, cell migration and cellular transformation and is one of the specific mRNA markers for circulating tumor cells in patients with gastrointestinal cancer. Here, for the first time, we found that AGR2 protein is expressed at a high level in CRC cells. The facts that AGR2 overexpression may provide a survival benefit for tumor cells and that its enhanced expression is almost completely restricted to malignant tissues make AGR2 a promising target for the development of immunotherapeutic strategies.
Although several types of tumor antigens have been applied in CRC, the identification of novel tumor antigens is urgently needed to improve the efficacy of DC-based cancer immunotherapy against CRC. In the present study, we demonstrated that AGR2 protein is expressed on the surface of most CRC cell lines, indicating that AGR2 might be an excellent candidate as a tumor-associated antigen in CRC. To determine whether AGR2 can be used as a tumor-associated antigen in CRC, we identified and synthesized five AGR2 peptides, P1, P2, P3, P4 and P5, after reviewing the AGR2 sequence for predictive HLA-A*0201-binding motifs. Among the peptides we identified, AGR2 peptides P2 and P4 were shown to have potential to generate AGR2 peptide-specific CTLs. Therefore, we identified AGR2 peptides for HLA-A*0201 molecules and generated AGR2 peptide-specific CTLs from HLA-A*0201 1 donors. The CTLs had strong cytolytic acitivity against AGR2 peptide-pulsed T2 cells and HLA-A*0201 1 AGR2-positive CRC cell lines, including HCT-8 and DLD1, suggesting that they may be promising effector cells for immunotherapy in CRC. Therefore, AGR2 is as an attractive candidate for DC-based immunotherapy designed for CRC.
Previous studies showed that some 'CTL epitopes' identified in vitro had little immunogenic activity in vivo and could not prime specific CTLs, partly because these peptides could not effectively be processed and presented by APCs. [27] [28] [29] Therefore, further studies will be focused on the in vivo immunogenicity of the peptides in order to prove these AGR2 P2 and P4 peptides as 'true' CTL epitopes. HLA-A*0201 transgenic mice will be immunized with AGR2 peptide P2 and P4, and the induced CTLs will be investigated. Furthermore, the antitumor effects of these CTLs using mice bearing AGR2 positive CRC cells will be studied to confirm the feasibility of T-cell epitopes from AGR2 as a target antigen for CRC in clinical applications.
In conclusion, the results of our study show that AGR2 peptidespecific CTLs can be generated by stimulating autologous T cells with DCs pulsed with AGR2 peptide P2 or P4. These CTLs may be promising effector cells for immunotherapy in CRC, because they are potent killer cells that are able to specifically and effectively lyse target cells, including T2 loaded with AGR2 peptide P2 or P4 and AGR2-positive CRC cells in vitro. Thus, this study is the first to provide a pivotal evidence to support the application of AGR2-based immunotherapy in CRC patients.
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